SLS News and Press, SELLAS Life Sciences Group Inc.

2024-05-14 16:58:41 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout Sellas reports positive Phase 2 data from AML study, files for patent SELLAS Life Sciences announces IDMC's recommendation of continuing REGAL...

- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: IDMC to Reconvene in June - - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S - ...

2024-05-07 08:00:00 ET Summary Welcome to another installment of our monthly Rare Stock Picks series. Today, we're highlighting April 2024 investment picks you may have missed. As you know, some Seeking Alpha analysts are more discerning by nature. Others are finding compelling id...

2024-05-01 10:23:01 ET More on SELLAS Life Sciences, TG Therapeutics, etc. Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout TG Therapeutics: The Cloud Over Briumvi TG Therapeutics: BRIUMVI Development Could Lead To Great Results TG The...

- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential – - 100% Overall Response Rate in Patients with ASXL1 Mutation in the SLS009 30mg BIW Cohort to Date, Al...

2024-04-29 08:54:27 ET More on SELLAS Life Sciences Sellas Life Sciences Group: A Lottery Ticket With An Estimated 6x Payout SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24 SELLAS Life Sciences looks to raise $20M in a direct offering Seeking Alpha&#x...

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of Phase 3 REGAL Trial Patients Treatment and Follow-Up Without Any Modifications – – IDMC Will Convene Again Ahead of Scheduled IDMC Charter M...

2024-04-19 13:49:43 ET Summary SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen,...

2024-03-28 16:57:07 ET More on SELLAS Life Sciences SELLAS Life Sciences looks to raise $20M in a direct offering Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Seeking Alpha’s Quant Rating on SELLAS Life Sciences Hist...

2024-03-28 16:54:11 ET More on SELLAS Life Sciences SELLAS Life Sciences looks to raise $20M in a direct offering Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Seeking Alpha’s Quant Rating on SELLAS Life Sciences Re...